Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer andBRAFmutation
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer andBRAFmutation
Authors
Keywords
-
Journal
Cancer Medicine
Volume 6, Issue 3, Pages 555-562
Publisher
Wiley
Online
2017-01-30
DOI
10.1002/cam4.1014
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
- (2016) Rafael Caparica et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
- (2015) Oliver Gautschi et al. Journal of Thoracic Oncology
- High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules
- (2015) Chunyan Wu et al. Journal of Thoracic Oncology
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma
- (2015) Zhenxiang Li et al. Thoracic Cancer
- Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma
- (2015) Ling Shan et al. PLoS One
- Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine
- (2015) Gavin M. Wright et al. Oncotarget
- TheBimdeletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer
- (2014) Mingchuan Zhao et al. CANCER
- Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboringBRAFmutations in the Lung Cancer Mutation Consortium
- (2014) Liza C. Villaruz et al. CANCER
- Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers
- (2014) Anya M. Litvak et al. Journal of Thoracic Oncology
- BRAF-mutations in non-small cell lung cancer
- (2014) Odd Terje Brustugun et al. LUNG CANCER
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAF Mutations in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
- (2014) Dong Chen et al. PLoS One
- Whole Brain Radiotherapy Plus Concurrent Chemotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: A Meta-Analysis
- (2014) Hong Qin et al. PLoS One
- Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients
- (2014) Xuefei Li et al. Translational Oncology
- Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations
- (2013) T. Kinno et al. ANNALS OF ONCOLOGY
- Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer
- (2013) S. Cardarella et al. CLINICAL CANCER RESEARCH
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
- (2011) Antonio Marchetti et al. JOURNAL OF CLINICAL ONCOLOGY
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- (2011) William D. Travis et al. Journal of Thoracic Oncology
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- New driver mutations in non-small-cell lung cancer
- (2011) William Pao et al. LANCET ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
- (2010) H. Yang et al. CANCER RESEARCH
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now